SPOTLIGHT: Positive Velcade data fuels stock rise

Shares of Millennium Pharmaceuticals shot up this morning after the company announced that a late-stage trial of Velcade proved effective against multiple myeloma. Researchers stopped the trial so that all the participants could receive the drug, which is also being developed for non-Hodgkin's lymphoma. Release

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.